Exelgyn is a global pharmaceutical company specialising in women’s healthcare. Its mission is to further improve healthcare for women worldwide and give them more autonomy. The company is known to be a pioneer in medical termination of pregnancy in Europe and export market and continue striving to ensure women access to this safe and effective method.
Currently, Exelgyn’s products (registered on the WHO list of essential medicines) are marketed in more than 30 countries which has enabled millions of women to terminate their unwanted pregnancy.
Exelgyn is committed to support both healthcare professionals and women throughout each step of a medical termination of pregnancy. Exelgyn intends to communicate smartly to make sure that patients and physicians have the information they need to make appropriate choices about abortion methods.


The scientific committee is composed of European gynaecologists/obstetricians:
Christian FIALA (Austria)
Marek LUBUSKY (Czech Republic)
Aubert AGOSTINI (France)
Mirella PARACHINI (Italy)
Teresa BOMBAS (Portugal)
Roberto LERTXUNDI (Spain)


We want to thank our correspondents who have freely completed the questionnaires used to collect the data (e.g., abortion statistics) of the present site, and in particular:
Nausikaä MARTENS (Belgium)
Vesna STEPANIC (Croatia)
Øjvind LIDEGAARD (Denmark)
Sharon CAMERON (England & Wales)
Helle KARRO (Estonia)
Oskari HEIKINHEIMO (Finland)
Ines THONKE (Germany)
Gyula CSERMELY (Hungary)
Áine KAVANAGH (Ireland)
Lina ČIAPLINSKIENĖ (Lithuania)
Catherine CHERY (Luxembourg)
Mette LØKELAND (Norway)
Krystyna KACPURA (Poland)
Bojana PINTER (Slovenia)
Helene HULDI (Switzerland)